Stocks and Investing
Stocks and Investing
Tue, May 17, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Louise Chen Maintained (SPRO) at Buy with Decreased Target to $5 on, May 17th, 2022
Louise Chen of Cantor Fitzgerald, Maintained "Spero Therapeutics, Inc." (SPRO) at Buy with Decreased Target from $27 to $5 on, May 17th, 2022.
Louise has made no other calls on SPRO in the last 4 months.
There are 3 other peers that have a rating on SPRO. Out of the 3 peers that are also analyzing SPRO, 2 agree with Louise's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold and Decreased Target to $2 on, Wednesday, May 4th, 2022
- Ritu Baral of "Cowen & Co." Downgraded from Buy to Hold on, Wednesday, May 4th, 2022
This is the rating of the analyst that currently disagrees with Louise
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $37 on, Monday, April 18th, 2022
Contributing Sources